Copyright: Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！ 京ICP备19006400号-1 Powered by 300.cn
美科
Links：
Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction
Source:
Release time：
2018/09/12 15:34
Page view
With a license granted by CardioCell LLC (a shareholding company of Stemedica) to treat cardiovascular indications with it-hMSCs, ALTACO XXI from Kazakhstan successfully completed a Phase III clinical trial in Kazakhstan and submitted an application for listing the product as a new drug to Kazak authorities. On September 12, 2018, the Ministry of Kazakhstan approved the application of Stemedica manufactured stem cells as a therapy to acute myocardial infarction, officially bringing it-hMSCs into clinical settings.
